Fatma Niang joined Chilmark Research this month. She brings a strong clinical research background to the table and we’re excited to have her!
Meet Fatma, Chilmark’s Newest Analyst!
read more
Healthcare Data Platforms: Getting to Network Effects with Jonathan Bush
Zus CEO Jonathan Bush joins us to discuss the network effect, the institution of the claim, and how to truly innovate in healthcare.
HIMSS22 Executive Interviews: Interoperability and Continuity of Care Lead the Discussion
The Chilmark team met with a wide array of leaders in the health IT space at HIMSS22. Take a look at some highlights in advance of our interview videos.
HIMSS21 Interviews: Castell Health’s Andrew Sorenson on Analytics for PHM During a Pandemic
Recorded on location at HIMSS21 in Las Vegas. Listen in as Andrew Sorenson, Chief Analytics...
Digital Therapeutics: Market Issues for an Emerging Technology [Chilmark Monitor]
Digital Therapeutics (DTx) entered the discourse of digital health nearly a decade ago but have yet to reach a broad consumer market due to lack of mature payment models and support from PBMs. The mainstreaming of DTx at the consumer level still has a distance to go to reach mainstream consumers and lack of payment models is one of the primary constraints.
Setting the Stage: Integration Infrastructure
In this hot take, John and Brian discuss the modern IT infrastructure that enables interoperability.
Looking to the Future – 2021 Predictions
Unlike past years when we have written a post evaluating how well our predictions for that year...
COVID-19: A Forcing Function for Value Based Care?
COVID-19 is alive and well in the U.S. In the last six days alone, COVID cases have increased by...
Will the New Interoperability Rules Tame or Be Tamed by Fees?
The healthcare exchange status quo got a boost last week in a legal victory for Ciox Health. The...